Ireland high drug prices cannot be justified

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Ireland high drug prices cannot be justified

Home/Pharma News | Posted 22/11/2013 0 Post your comment

The European Commission’s troika mission to Ireland has told Government TDs (Members of Parliament) that the cost of pharmaceutical drugs in the country cannot be justified. Drug prices in the country have been found to be at least three times more expensive than in the UK.

The head of the European Commission’s troika mission, Mr Istvan Szekely, EC Director of Economic and Financial Affairs, told the delegation of Fine Gael and Laour TDs that pharmaceutical drug costs were an outstanding issue and were ‘not sustainable’.

Savings have been proposed by Health Minister Dr James Reilly through a review of medical cards and through work-related savings. But the troika believes there are still substantial savings to be made through increased use of generics, which would be ‘less painful’ than medical card changes.

Penetration of generics into the Irish market is amongst the lowest in Europe, with current use of generics at a mere 18% of prescribed medicines [1].

Some progress has been made. Ireland introduced a new bill – Health (Pricing and Supply of Medical Goods) Bill 2012 – on 16 September 2012 to introduce a system of reference pricing and generics substitution in Ireland [2]. The first drug to be subject to the reference pricing system, high-cholesterol treatment atorvastatin, has already produced price reductions of 70% for the Irish Health Service Executive (HSE). Reference prices are being introduced on a phased basis and the next drug in line is proton pump inhibitor esomeprazole.

The move to reference pricing is expected to ‘result in significant reductions in the price of generics which are currently amongst the highest in Europe at 50% above the European Union average and up to three times the UK price’, according to Irish Pharmaceutical Healthcare Association (IPHA) Chief Executive, Ms Anne Nolan.

Despite the move to reference pricing, Mr Szekely’s comments increase pressure on Dr Reilly to rein in pharmaceutical firms, hospitals’ and doctors’ practices and negotiate a greater and cheaper use of generics throughout Ireland.

Related articles

Generics policies in Europe have room for improvement

Generics substitution: Ireland’s plan for reference pricing

References

1. GaBI Online - Generics and Biosimilars Initiative. Use of generic medicines in Ireland [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 22]. Available from: www.gabionline.net/Generics/Research/Use-of-generic-medicines-in-Ireland

2. GaBI Online - Generics and Biosimilars Initiative. Cost savings from use of generic medicines in Ireland [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 22]. Available from: www.gabionline.net/Generics/Research/Cost-savings-from-use-of-generic-medicines-in-Ireland

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: DOHC, IPHA, Irish Examiner